SK282957B6 - Spôsob prípravy vyčistenej deaminovanej DNázy, deaminovaná a nedeaminovaná ľudská DNáza, DNázový a farmaceutický prostriedok - Google Patents

Spôsob prípravy vyčistenej deaminovanej DNázy, deaminovaná a nedeaminovaná ľudská DNáza, DNázový a farmaceutický prostriedok Download PDF

Info

Publication number
SK282957B6
SK282957B6 SK1495-94A SK149594A SK282957B6 SK 282957 B6 SK282957 B6 SK 282957B6 SK 149594 A SK149594 A SK 149594A SK 282957 B6 SK282957 B6 SK 282957B6
Authority
SK
Slovakia
Prior art keywords
dnase
deaminated
human dnase
amino acid
human
Prior art date
Application number
SK1495-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK149594A3 (en
Inventor
John Frenz
Steven J. Shire
Mary B. Sliwkowski
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of SK149594A3 publication Critical patent/SK149594A3/sk
Publication of SK282957B6 publication Critical patent/SK282957B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SK1495-94A 1992-06-08 1993-05-28 Spôsob prípravy vyčistenej deaminovanej DNázy, deaminovaná a nedeaminovaná ľudská DNáza, DNázový a farmaceutický prostriedok SK282957B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (2)

Publication Number Publication Date
SK149594A3 SK149594A3 (en) 1996-01-10
SK282957B6 true SK282957B6 (sk) 2003-01-09

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1495-94A SK282957B6 (sk) 1992-06-08 1993-05-28 Spôsob prípravy vyčistenej deaminovanej DNázy, deaminovaná a nedeaminovaná ľudská DNáza, DNázový a farmaceutický prostriedok

Country Status (30)

Country Link
US (4) US5279823A (ro)
EP (2) EP1013284B1 (ro)
JP (1) JP3383307B2 (ro)
KR (2) KR100302092B1 (ro)
AT (2) ATE195340T1 (ro)
AU (1) AU682822B2 (ro)
BG (1) BG62335B1 (ro)
BR (1) BR9306670A (ro)
CA (1) CA2137237C (ro)
CZ (1) CZ293105B6 (ro)
DE (3) DE69329200T2 (ro)
DK (1) DK0644932T3 (ro)
ES (1) ES2150447T3 (ro)
FI (1) FI945549A (ro)
GB (1) GB2282140B (ro)
GE (1) GEP20002300B (ro)
GR (1) GR3034718T3 (ro)
HU (1) HU219549B (ro)
IL (1) IL105724A (ro)
MD (1) MD960288A (ro)
NO (1) NO318644B1 (ro)
NZ (1) NZ253559A (ro)
PL (1) PL175873B1 (ro)
PT (1) PT644932E (ro)
RO (1) RO117188B1 (ro)
RU (1) RU2238320C2 (ro)
SK (1) SK282957B6 (ro)
TJ (1) TJ396B (ro)
UA (1) UA46693C2 (ro)
WO (1) WO1993025670A1 (ro)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853121B1 (en) * 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
DE69535787D1 (de) * 1994-03-04 2008-08-28 Genentech Inc Verbesserte dnase flüssige lösungen
JPH09512715A (ja) * 1994-05-05 1997-12-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトｄｎａｓｅ
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
EP1045028A1 (en) * 1994-09-06 2000-10-18 Seiichi Tanuma Deoxyribonucleases
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
EP0879289B1 (en) * 1996-02-05 2006-07-05 Genentech, Inc. Human dnase resistant to actin inhibition
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
WO2001058514A1 (en) * 2000-02-11 2001-08-16 Profile Respiratory Systems Limited Drug delivery apparatus
ES2312447T3 (es) * 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
LT1543038T (lt) 2002-09-11 2017-07-10 Genentech, Inc. Baltymo gryninimas
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) * 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
EP2086642B1 (en) 2006-10-18 2014-06-25 Periness Ltd. Dnase for the treatment of male sub-fertility
KR20140015166A (ko) * 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
GB2474225A (en) * 2009-07-21 2011-04-13 Biotec Pharmacon Asa DNase for decontamination of reverse transcription and amplification reactions
EP3318634A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
MX2016017115A (es) * 2014-06-25 2018-01-12 Jhl Biotech Inc Metodos y reactivos para la purificacion de proteinas.
WO2016067944A1 (ja) 2014-10-31 2016-05-06 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
US20180214576A1 (en) * 2015-07-28 2018-08-02 University Of Massachusetts Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP4157309A1 (en) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
EP0853121B1 (en) * 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
EP0644932B1 (en) 2000-08-09
EP0644932A1 (en) 1995-03-29
JP3383307B2 (ja) 2003-03-04
NO318644B1 (no) 2005-04-25
EP1013284A3 (en) 2000-08-30
TJ396B (en) 2004-12-29
ATE455557T1 (de) 2010-02-15
US5279823A (en) 1994-01-18
US6440412B1 (en) 2002-08-27
PL175873B1 (pl) 1999-02-26
WO1993025670A1 (en) 1993-12-23
DE69329200D1 (de) 2000-09-14
KR100302092B1 (ko) 2001-10-22
PT644932E (pt) 2001-02-28
RU94046424A (ru) 1997-03-10
RU2238320C2 (ru) 2004-10-20
ES2150447T3 (es) 2000-12-01
HU9403512D0 (en) 1995-02-28
EP1013284B1 (en) 2010-01-20
ATE195340T1 (de) 2000-08-15
EP1013284A2 (en) 2000-06-28
BR9306670A (pt) 1998-12-08
KR100323357B1 (ko) 2002-02-19
DK0644932T3 (da) 2001-01-02
AU682822B2 (en) 1997-10-23
NO944752D0 (no) 1994-12-08
US5783433A (en) 1998-07-21
RO117188B1 (ro) 2001-11-30
JPH07507455A (ja) 1995-08-24
GEP20002300B (en) 2000-11-25
HU219549B (hu) 2001-05-28
GB9423695D0 (en) 1995-01-11
BG62335B1 (bg) 1999-08-31
CA2137237C (en) 2004-10-26
HUT70468A (en) 1995-10-30
DE69329200T2 (de) 2001-04-26
GB2282140A (en) 1995-03-29
CA2137237A1 (en) 1993-12-23
DE69334317D1 (de) 2010-03-11
CZ293105B6 (cs) 2004-02-18
IL105724A0 (en) 1993-09-22
MD960288A (ro) 1998-01-31
FI945549A0 (fi) 1994-11-25
AU4398193A (en) 1994-01-04
NZ253559A (en) 1996-11-26
IL105724A (en) 1997-06-10
US6932965B2 (en) 2005-08-23
UA46693C2 (uk) 2002-06-17
BG99234A (bg) 1995-07-28
GR3034718T3 (en) 2001-01-31
DE4392749T1 (de) 1995-07-20
FI945549A (fi) 1994-11-25
CZ303294A3 (en) 1995-06-14
NO944752L (no) 1994-12-08
US20030077267A1 (en) 2003-04-24
GB2282140B (en) 1996-04-17
SK149594A3 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
SK282957B6 (sk) Spôsob prípravy vyčistenej deaminovanej DNázy, deaminovaná a nedeaminovaná ľudská DNáza, DNázový a farmaceutický prostriedok
Stevenson et al. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece.
Pike et al. Epidermal growth factor stimulates the phosphorylation of synthetic tyrosine-containing peptides by A431 cell membranes.
Proost et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation
AU2002254683B2 (en) Binding molecules for Fc-region polypeptides
JP2006519800A (ja) 未分化リンパ腫キナーゼアッセイ、試薬及びその組成物
US20030088057A1 (en) Peptide substrates phosphorylated by p21-activaged protein kinase statement regarding federally sponsored reasearch or development
Saheki et al. Peptide structures of pyruvate kinase isozymes: 1. Comparison of the four pyruvate kinase isozymes of the rat
Tanaka et al. Proteasomes (multicatalytic proteinase complexes) in eukaryotic cells
CN105017410B (zh) 一种b区部分缺失型重组人凝血因子ⅷ
Zhou et al. Heparin protein interactions
US20090093038A1 (en) Method for the production of pure virally inactivated butyrylcholinesterase
Lu et al. Isolation and Characterization of Human Tissue Kallikrein Produced inEscherichia coli: Biochemical Comparison to the Enzymatically Inactive Prokallikrein and Methionyl Kallikrein
EP1179050B1 (en) Method for the purification of protein kinase by affinity chromatography
US7164002B2 (en) FVIIa antagonists
McILHINNEY et al. Characterization, regional and subcellular distribution of an N-myristoyl-CoA: glycyltransferase activity in rat brain

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20130528